Key Short-Chain PFAS Not an Endocrine Disruptor

A critical review of the potential endocrine activity of perfluorohexanoic acid (PFHxA), a key short-chain perfluoroalkyl substance (PFAS), published in the peer-reviewed journal Regulatory Toxicology and Pharmacology concluded that PFHxA would not be characterized as an endocrine disruptor as defined by the World Health Organization. The weight of the evidence analysis evaluated the potential endocrine disruptor activity of PFHxA as defined by the World Health Organization.

According to the peer reviewed analysis:

“Overall, PFHxA showed no endocrine effects in Japanese medaka, juvenile rainbow trout, chickens or re-productive parameters in northern bobwhite with no significant activity in rodent repeated-dose toxicity, life-time cancer, or reproductive and developmental studies. In vitro, there was weak or negative activity for T [thyroid] transport protein or activation of E [estrogen], A [androgen] or T [thyroid] receptors. PFHxA was also negative in vitro and in vivo for disrupting steroidogenesis.”

PFHxA is a break down product of the C6 short-chain fluorotelomer-based products relied on in today’s stain-resistant carpeting, medical garments, first responder gear, and class B fire fighting foams. PFHxA also has some limited uses. PFHxA is a substance used by regulators to assess the safety of the short-chain fluorotelomer-based products.

Further available data, much of which can be found here, have found there is no indication of high bioaccumulation of PFHxA and that it does not become concentrated inside the bodies of living organisms. PFHxA is also not carcinogenic, mutagenic, or genotoxic. PFHxA is also not a reproductive or developmental toxicant. You can access much of the available data on PFHxA on the FluoroCouncil website.